Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;128(5):642-648.
doi: 10.1111/bcpt.13578. Epub 2021 Mar 13.

Predictive biomarkers and clinical evidence

Jan Trøst Jørgensen  1
Affiliations
Review

Predictive biomarkers and clinical evidence

Jan Trøst Jørgensen. Basic Clin Pharmacol Toxicol. 2021 May.

Abstract

Predictive biomarkers play an important role in our efforts to individualize pharmacotherapy, and within recent years, a number of different types of assays have been introduced. These biomarkers may potentially support the selection and dosage of specific drugs in order to maximize efficacy and minimize adverse reactions in the individual patient. However, in many instances, the scientific and clinical evidence is insufficient to support the prescribing decision. When predictive biomarkers are used to guide pharmacotherapy, it is important to secure that decisions are based on solid clinical evidence. Here, the regulatory authorities, especially the FDA, have been at the forefront in relation to regulate this type of biomarker assay in order to secure patient safety. The approval process for companion diagnostics is an example of this effort, where the scientific validity of the biomarker and assay is in focus. With the approaching implementation of the new IVD Regulation, greater attention will also be paid to analytical and clinical validity of biomarker assays in the EU. For any type of predictive biomarker assay, including pharmacogenetic and tumour profiling tests, the clinical evidence needs to be in place before they are used routinely in the clinic.

Keywords: European Medicines Agency; FDA; companion diagnostics; genomic profiling; pharmacogenetics; precision medicine; predictive biomarkers.

PubMed Disclaimer

References

REFERENCES

    1. Jørgensen JT. Twenty years with personalized medicine: Past, present, and future of individualized pharmacotherapy. Oncologist. 2019;24(7):e432-e440.
    1. FDA News Release. FDA issues warning letter to genomics lab for illegally marketing genetic test that claims to predict patients’ responses to specific medications. April 4, 2019. https://www.fda.gov/news-events/press-announcements/fda-issues-warning-l.... Accessed December 15, 2020
    1. FDA Statement: Jeffrey Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health and Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research on agency’s warning to consumers about genetic tests that claim to predict patients’ responses to specific medications. November 1, 2018. https://www.fda.gov/news-events/press-announcements/jeffrey-shuren-md-jd.... Accessed December 12, 2020
    1. FFA Statement: FDA Announces Collaborative Review of Scientific Evidence to Support Associations Between Genetic Information and Specific Medications. February 20, 2020. https://www.fda.gov/news-events/press-announcements/fda-announces-collab.... Accessed December 9, 2020
    1. FDA. Table of Pharmacogenetic Associations. February 25, 2020. https://www.FDA.gov/medical-devices/precision-medicine/table-pharmacogen.... Accessed December 9, 2020

MeSH terms

LinkOut - more resources